Abstracts tagged "cytokines"

Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 31 • 2014 ACR/ARHP Annual Meeting
Interaction of FGF-8 and TNF-a in the Regulation of BMP-Induced Osteoblast Differentiation
Takayuki Katsuyama¹, Fumio Otsuka², Mariko Narazaki¹, Ken-ei Sada¹, Kenichi Inagaki¹, Jun Wada¹ and Hirofumi Makino¹, ¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose: Osteoblasts and osteoclasts play important roles in the bone remodeling. When the balance between these cells is disrupted, bone loss or aberrant bone…
Abstract Number: 2462 • 2014 ACR/ARHP Annual Meeting
Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda^1,2, Yasushi Miura^2,3, Toshihisa Maeda², Shinya Hayashi² and Masahiro Kurosaka², ¹Orthopaedic Surgery, Kakogawa City Hospital, Kakogawa, Japan, ²Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand, LIGHT, and…
Abstract Number: 1461 • 2014 ACR/ARHP Annual Meeting
Quantitave Analysis of Cadherin-11 and Beta-Catenin Signaling during Proliferation of Rheumatoid Arthritis-Derived Synovial Fibroblast Cells
Ryosuke Yoshioka, Yasuhiro Kita, Asako Nagahira, Atsushi Manno, Naoyuki Makita, Urara Tomita and Masao Murakawa, Asubio Pharma Co., Ltd., Kobe, Japan
[Background/Purpose ] Cadherin-11 (CDH11) is a cadherin adhesion molecule that anchors b-catenin, and is involved with various functions of synovial fibroblast cells (SFCs) during the development…
Abstract Number: 2363 • 2014 ACR/ARHP Annual Meeting
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis
Yusuke Takahashi¹, Minoru Fujimoto², Satoshi Serada³ and Tetsuji Naka², ¹a doctoral student, Osaka university, Suita city, Japan, ²Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan, ³7-6-8, Saito-asagi, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan
Background/Purpose C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently…
Abstract Number: 1195 • 2014 ACR/ARHP Annual Meeting
Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis
Mary Connolly, Trudy McGarry, Monika Biniecka, Douglas J. Veale and Ursula Fearon, Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland
Background/Purpose: The inflammasome is a large multiprotein complex which plays a key role in innate immunity by mediating the production of pro-inflammatory cytokines interleukin-1β (IL-1β)…
Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…
Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Daniel J. Wallace¹, Igor Gavin², Oleksiy Karpenko² and Bruce S. Gillis³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Illinois College of Medicine at Chicago, Chicago, IL, ³Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…
Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…
Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Sebastian Unizony¹, John Stone² and Brian Keroack³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Maine Medical Center, Tufts University Medical School, Maine, ME
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…
Abstract Number: 643 • 2013 ACR/ARHP Annual Meeting
Potential Immunopathological Roles Of The Novel Anti-Inflammatory Cytokine Interleukin-35 In Patients With Systemic Lupus Erythematous
Zhe Cai¹, Chun-Kwok Wong² and Lai Shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: IL-35, a dimeric protein with two subunits, IL-12A (p35) and Epstein-Barr virus induced 3, is a novel IL-12 cytokine family regulatory T-cells (Treg)-specific immunosuppressive/anti-inflammatory…
Abstract Number: 2499 • 2013 ACR/ARHP Annual Meeting
Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis
Uta Syrbe¹, Janine Bleil², Rene Maier³, Heiner Appel¹ and Joachim Sieper⁴, ¹Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ²Charité, Berlin, Germany, ³Charite, Berlin, Germany, ⁴Charitè Campus Benjamin Franklin, Berlin, Germany
Background/Purpose: Inflammation within sacroiliac joints and within the spine is a hallmark of ankylosing spondylitis (AS). Apart from nonsteroidal anti-rheumatic drug (NSAID) treatment, inhibition of…
Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Bjorn Hartmann¹, Joyce Liao², Michael H. Weisman³, Kenneth J. Warrington⁴, Jorg J. Goronzy¹ and Cornelia M. Weyand⁵, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].